er wordt geen aandoening bestudeerd, het betreft gezonde proefpersonen muscle fatigue
Conditions
Interventions
None listed
Sponsors
Stichting Opleiding Musculoskeletale Therapie (SOMT) University Campus Amersfoort
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Young, healthy subjects aged 18-30 years: completely healthy, no medication use, no impairments interfering with muscle fatigue resistance test, normal physical activity (i.e. at least 150 minutes/week at moderate intensity but no competitive sports). Community-dwelling subjects aged >30years: living independently in the community, no functional disability of the dominant upper extremity (paresis/paralysis, tremor or recent surgery), normal cognitive functioning (Mini-Mental State Examination [MMSE] score >23/3016).
Exclusion criteria
Exclusion criteria: Pregnant women are excluded. Acute or uncontrolled conditions, chronic inflammatory pathology and/or central nervous disease (e.g. Parkinson*s disease, Multiple Sclerosis, Cerebro-Vascular Accident).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue resistance: assessed by both the Martin Vigorimeter and the JAMAR dynamometer in a random order (see appendix 1 for detailed description). Both tests will be performed at the same day with at least 1 hour interval. In a subgroup of participants the fatigue resistance test will be performed by a modified digital manometer and Dynamometer G200 system, and with simultaneous synchronized sEMG recording of the fore-arm muscle (all connected to a MPAQ universal amplifier, Maastricht Instruments) in order to appraise muscle fatigue curves and related muscle activation. Area under the curve and other derived muscle endurance parameters are calculated as described previously. | — |
Secondary
| Measure | Time frame |
|---|---|
| Figures refer to reference list in the protocol. Explanatory outcomes Hand function & pain: Perceived pain in the hands directly following the fatigue resistance test (Numeric Rating Scale), Hand function(Australian/Canadian Hand Osteoarthritis Index) (17), presence/number of phalangeal nodules (using standard photographic registration and visual counting). In a subgroup of participants a standard ultrasonographic assessment of the hands will be performed in order to assess the degree of osteoarthritic lesions (18). Sarcopenia assessment according to European consensus criteria (19) including physical functioning (Short Physical Performance Battery (20), Timed Up-and-Go test (21), 2 minutes step test (22), flexicurve ruler (23) and body composition (Bio-electrical Impedance, Quadscan4000, Bodystat, Ashhurst, New Zealand) (24). Self-perceived fatigue & physical activity: MOB-Tiredness scale (25), Multidimensional Fatigue Inventory (26) and Yale Physical Activity Questionnaire (27). General health and quality of life: co-morbidity & medication use using self-report questionnaires; Medical Outcome Study (MOS) Short-form (28); cognitive functioning (MMSE (16); dependency for activities of daily life (basic (29) & instrumental (30) ADL) Inflammatory parameters: serum obtained from non-fasting venepuncture, stored at -80°C for ulterior determination of circulating markers of inflammation (including IL-6, sTNFR1, IL-10, IL-1RA, IL-8, HSP70) as described previously (31,10). | — |
Countries
Netherlands
Outcome results
None listed